Publications by authors named "J L Molinuevo"
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluorodeoxyglucose and 18F-flutemetamol PET scanning.
View Article and Find Full Text PDFIntroduction: Brain glucose hypometabolism is a preclinical feature of Alzheimer's disease (AD). Dietary omega-3 fatty acids promote brain glucose metabolism, but clinical research is incipient. Circulating omega-3s objectively reflect their dietary intake.
View Article and Find Full Text PDFArticle Synopsis
- Cerebral blood flow (CBF) is reduced in Alzheimer's disease (AD) patients, especially those with cognitive impairment (CI), and the study aimed to assess a new method called time-encoded arterial spin labeling (te-ASL) for measuring these changes.
- The researchers compared te-ASL to a traditional method (single-postlabel delay ASL) in 59 adults categorized as cognitively unimpaired (CU) and those with positive AD biomarkers, finding that te-ASL was better at detecting CBF reductions in CU Aβ+ and CI Aβ+ individuals.
- Results showed that lower CBF in CU participants was associated with changes in biomarkers related to AD, cognitive function, and synaptic health, highlighting the importance
Alzheimer’s disease can be treated by targeting amyloid-β plaques and diagnosed in vivo by biomarkers, prompting the revision of criteria for the diagnosis and staging of this disease.
View Article and Find Full Text PDFIntroduction: Leukocyte telomere length (LTL) is an objective biomarker of biological aging, and it is proposed to play a crucial role in Alzheimer's disease (AD) risk. We aimed at evaluating the cross-sectional association between LTL and cognitive performance in middle-aged cognitively unimpaired individuals at increased risk of AD.
Methods: A total of 1520 participants from the ALFA cohort were included.